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Abstract: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by
progressive loss of lower and upper motor neurons (MN) leading to muscle weakness, paralysis
and eventually death. Although a highly varied etiology results in ALS, it broadly manifests itself
as sporadic and familial forms that have evident similarities in clinical symptoms and disease
progression. There is a tremendous amount of knowledge on molecular mechanisms leading to loss
of MNs and neuromuscular junctions (NMJ) as major determinants of disease onset, severity and
progression in ALS. Specifically, two main opposing hypotheses, the dying forward and dying back
phenomena, exist to account for NMJ denervation. The former hypothesis proposes that the earliest
degeneration occurs at the central MNs and proceeds to the NMJ, whereas in the latter, the peripheral
NMJ is the site of precipitating degeneration progressing backwards to the MN cell body. A large
body of literature strongly indicates a role for the immune system in disease onset and progression
via regulatory involvement at the level of both the central and peripheral nervous systems (CNS and
PNS). In this review, we discuss the earliest reported immune responses with an emphasis on newly
identified immune players in mutant superoxide dismutase 1 (mSOD1) transgenic mice, the gold
standard mouse model for ALS.
Keywords: amyotrophic lateral sclerosis (ALS); immune response; neuroimmunology; motor
neuron disease
1. Amyotrophic Lateral Sclerosis (ALS)
Motor neuron diseases are devastating and encompass a variety of disorders that lead to death
of motor neurons and resulting loss of motor function, dysphagia and respiratory failure. Of these
diseases, amyotrophic lateral sclerosis (ALS) is the most common. ALS frequently afflicts adults in
middle age (40–60 years old) with an average lifespan of 3–5 years following diagnosis [1]. Most cases
of ALS are sporadic in nature, while approximately 20% of familial forms of ALS (FALS) are caused
by mutations in the gene for copper/zinc superoxide dismutase (SOD1). Clinically, ALS treatment
comprises of riluzole which extends lifespan moderately and edaravone, a free radical scavenger
approved for clinical use recently in 2017. Although promising, edaravone confers neuroprotection
only when started during early stage of the disease with its long term clinical efficacy yet to be
established [2]. Despite the disadvantages of using rodent models of ALS overexpressing mSOD1,
it is the most widely used model and closely mimics the pathogenic progression observed in human
ALS [3].
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There is currently a delay of more than one year between symptom onset and clinical diagnosis,
likely due to the underestimation of initial symptoms by patients and clinicians as they are similar
to those resulting from various etiologies [4]. ALS is considered a diagnosis based on exclusion
of other possible causes. This delay represents a lost temporal opportunity for initiating therapies
in a timely manner to treat ALS. Before symptoms even begin, peripheral disconnection of motor
axons from target musculature is documented to take place in both ALS patients and mouse models
of the disease [5]. As there are currently no effective biomarkers for ALS, the delay between
peripheral disease initiation and symptom onset represents another lost therapeutic window of
opportunity. These issues underscore the critical need for better understanding of risk factors, initiators
of disease, and biomarkers for early identification of individuals at elevated risk for ALS development
and progression.
Research into the immune system influence in ALS has yielded important clues on possible
markers that could be targeted to tackle the disease before it has progressed too far. Much research
into immune system involvement in different stages of ALS disease has been covered to date [6,7].
However, recent research in ALS patients and animal models has identified a role for new immune
system components in disease onset and progression. This review will discuss these new findings
in the context of prior research and lay emphasis on the temporal and spatial effects of the observed
immune activation in ALS.
2. New Immune Players in ALS
In addition to MN cell intrinsic molecular defects, secondary mechanisms including toxic glial
microenvironment, immune system influence on glial activation and neuromuscular junction (NMJ)
maintenance, all converge to modify the disease course in ALS [8]. Here, we discuss the impact of
peripheral immune cell interactions with CNS resident glia on MNs and shed light on newly identified
interactions between immune system and each component of the NMJ.
2.1. Peripheral Immune System—CNS Glia Interactions
Selective reduction of mSOD1 expression in microglia or astrocytes significantly extends
the lifespan of ALS mice, thereby establishing a role for glial cells in MN degeneration [9,10].
Glial reactivity, hypertrophy and changes in inflammatory marker expression have been extensively
demonstrated in the mSOD1 model and post-mortem tissue of ALS patients [11]. There is also
a growing body of work suggesting peripheral immune system involvement in balancing glial
neurotrophic and neurotoxic functions in ALS. Accelerated disease progression is observed in mSOD1
mice crossed with T cell receptor β chain (TCRβ) deficient mice that lack αβ+ CD4+ and CD8+ T cells
relative to mSOD1 mice [12]. In this study, T cell deficiency leads to decreased microglial reactivity
with no effect on astrocytes. Thus, lack of T cells ablates a neuroprotective pathway involving reduced
production of neurotrophic factor, IGF-1, in mSOD1 microglia. When mSOD1 mice are bred to a
CD4−/− background that lack CD4+ T cells, a similar significant reduction in their lifespan is observed
relative to mSOD1 mice. The mSOD1 CD4−/− mice also exhibit attenuated microglial and astrocyte
reactivity. Lack of CD4+ T cells alters the glia phenotype towards toxicity, owing to reduced expression
of neurotrophic factors such as IGF-1, GDNF, BDNF; anti-inflammatory cytokines such as IL-4, TGF-β
and increased expression of proinflammatory molecules such as TNF-α, NOX2 in the lumbar spinal
cords of these mice [13]. In a more direct approach, this group also showed that passive transfer of
wild-type (WT) CD4+ T cells, or subpopulation of CD4+ T cells, namely, regulatory T cells (Tregs)
from stable disease phase mSOD1 mice leads to neuroprotection in mSOD1/RAG2−/− recipient mice.
The authors attribute the CD4+ T cell-mediated neuroprotection to the presence of IL-4+ Tregs, which in
turn promote anti-inflammatory M2-like microglia phenotype and their production of neurotrophic
factors. Extending these observations to human ALS patients, this study also reported decreased
numbers of Tregs in blood to correlate with faster disease progression. Contrary to this, Tregs isolated
from mSOD1 mice during the late rapid progressive phase and transferred into mSOD1/RAG2−/−
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recipients fails to prolong disease duration and extend survival [14]. Tregs, a distinct CD4+ T cell
subpopulation involved in self-tolerance and immune homeostasis, have well documented suppressive
effects on innate and adaptive immune cells [15]. The results from these studies suggest that the ability
of the early disease phase Tregs to sustain M2-like microglial responses is lost with disease progression
leading to a predominant M1-like microglial phenotype at end stage.
The T helper 2 (Th2) sub-population of CD4+ T cells have also been shown to be crucial in
sustaining MN survival after facial nerve axotomy (FNA), a peripheral nerve injury model [16].
Reconstitution of immunodeficient RAG2−/−mice with whole splenocytes or CD4+ T cells from WT
or mSOD1 donor mice leads to differences in the CNS molecular responses to FNA. Specifically,
RAG2−/− recipients supplemented with mSOD1 whole splenocytes show increased astrocyte
activation and neuronal cell death pathway triggers such as Fas and nNOS, potentially the underlying
cause of reduced MN survival in this group after FNA [17]. Taken together, these studies suggest that
peripheral immune cells, particularly CD4+ T cells modulate CNS neuroprotective pathways via a
direct impact on glial responses to disease or injury. On the other hand, a newer study in mSOD1
mice selectively overexpressing TGF-β in astrocytes shows reduced CD4+ T cell infiltration and their
increased polarization towards proinflammatory IFN-γ+ Th1 over IL-4 producing Th2 phenotype in
the spinal cord. Further, there was significant decrease in microglial immune activation markers and
IGF-1 expression in the lumbar spinal cord of these mice [18]. This study proposes higher astrocytic
TGF-β1 as a negative prognostic factor in mSOD1 mice owing to its inhibition of microglia and CD4+
T cell-mediated neuroprotective inflammation. Although neuroprotection conferred by CD4+ T cells is
well established, the nature and source of antigens (Ags) and the compartment (CNS or PNS) where
these lymphocytes are activated in ALS are currently unclear.
Another recent study discovered a role for MN-specific major histocompatibility complex (MHC)
class I molecules, that classically trigger CD8+ T cell based adaptive immune responses, in protection
from astrocyte-induced toxicity. MHC class I expression was highly localized to motor axons over
cell bodies and was nearly absent in spinal cords of end stage sporadic and familial ALS patients in
comparison to healthy controls. Furthermore, in contrast to WT, mSOD1 astrocytes when co-cultured
with MNs induces downregulation of MHC class I expression. Conditioned media from mSOD1
astrocyte cultures alone is sufficient to cause this downregulation via induction of endoplasmic
reticulum (ER) stress pathways in MNs. Overexpression of MHC class I in MNs rescues them from the
astrocyte-induced toxicity, delays disease progression and enhances survival in mSOD1 mice [19].
Overall, as summarized in Figure 1, glia-peripheral immune interactions have a strong influence
on neuronal health that during the early stages of ALS disease strive to sustain MN survival while
at the end stage, due to a vicious circle of excessive inflammation, become the pathological basis
for neurodegeneration.
2.2. Immune System Interactions with the Tripartite Neuromuscular Junction
A neuromuscular junction (NMJ), serving as the functional units for skeletal muscles,
are comprised of presynaptic MN axon terminals, the post-synaptic skeletal muscle and the synapse
associated glial cells, Schwann cells (SC; also referred to as perisynaptic or terminal Schwann cells, TSC).
Dynamic communication between all three components contributes to formation, maturation and
maintenance of NMJs; any perturbations in this crosstalk results in NMJ instability, axon retraction
and eventually muscular atrophy [20]. In fact, denervation in motor end plates is reported in mSOD1
mice as early as postnatal day (PND) 47, supporting the idea of distal axonal pathology preceding
neuronal degeneration and symptom onset in ALS [5] (Figure 2).
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Figure 1. CD4+ T cells tip the balance between glial neurotrophism and neurotoxicity. Circulating 
CD4+ T cells (specifically, Tregs and Th2 cells) via yet-to-be identified mechanisms promote 
microglial and astrocyte production of trophic factors and anti-inflammatory cytokines. Depletion of 
CD4+ T cells in mSOD1 mice via different genetic approaches switches them to an activated 
proinflammatory phenotype with neurotoxic properties. BDNF: brain-derived neurotrophic factor; 
ER: endoplasmic reticulum; GDNF: glial cell-derived neurotrophic factor; ; IGF-1: insulin-like growth 
factor 1; IL-4: interleukin-4; MHC: major histocompatibility complex class I; mSOD1:mutant SOD1; 
NOX2: NADPH oxidase isoform 2; Tregs: regulatory T cells ; Th2: T helper 2; TCRβ: T cell receptor β; 
TGF-β: transforming growth factor-β; TNF-α: tumor necrosis factor-α. 
 
Figure 2. A timeline of reported molecular, histological and functional events in the lifetime of 
mSOD1G93A mice. 
Research on CNS synaptic pruning led to the surprise identification of immune system 
components in mediating synapse elimination, particularly, during development. Examples of such 
molecules include the MHC class I proteins, associated accessory protein β2m and complement 
cascade proteins, immune molecules that are typically involved in pathogen elimination [21,22]. In 
contrast to prevalent dogma on lack of MHC expression in the CNS and the immune privilege to 
escape T cell recognition, reports on mRNA expression for MHC class I and β2m is response to virus 
infections or nerve injury dates back more than two decades [23]. For example, MHC class I is 
upregulated in rat facial MNs and skeletal muscle in response to FNA. Using a nerve cut vs crush 
injury, MHC class I is implicated to play a role in regeneration in this study [24]. Almost 20 years 
Figure 1. CD4+ T cells tip the balance between glial neurotrophism and neurotoxicity. Circulating CD4+
T cells (specifically, Tregs and Th2 cells) via yet-to-be identified mechanisms promote microglial and
astrocyte production of trophic factors and anti-inflammatory cytokines. Depletion of CD4+ T cells
in mSOD1 mice via different genetic approaches switches them to an activated proinflammatory
phenotype with neurotoxic properties. BDNF: brain-derived neurotrophic factor; ER: endoplasmic
reticulum; GDNF: glial cell-derived neurotrophic factor; ; IGF-1: insulin-like growth factor 1; IL-4:
interleukin-4; MHC: major histocompatibility complex class I; mSOD1:mutant SOD1; NOX2: NADPH
oxidase isoform 2; Tregs: regulatory T cells ; Th2: T helper 2; TCRβ: T cell receptor β; TGF-β:
transforming growth factor-β; TNF-α: tumor necrosis factor-α.
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Figure 2. A timeline of reported molecular, histological and functional events in the lifetime of
mSOD1G93A mice.
Research on CNS synaptic pruning led to the surprise identification of immune system
components in mediating synapse elimination, particularly, during development. Examples of such
molecules include the MHC class I proteins, associated accessory protein β2m and complement cascade
proteins, immune molecules that are typically involved in pathogen elimination [21,22]. In contrast to
prevalent dogma on lack of MHC expression in the CNS and the immune privilege to escape T cell
recognition, reports on mRNA expression for MHC class I and β2m is response to virus infections or
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nerve injury dates back more than two decades [23]. For example, MHC class I is upregulated in rat
facial MNs and skeletal muscle in response to FNA. Using a nerve cut vs crush injury, MHC class I is
implicated to play a role in regeneration in this study [24]. Almost 20 years later came the first evidence
for subcellular localization of MHC class I molecules in MN axons and their presynaptic terminals at
the NMJ. The expression is strongly upregulated after sciatic nerve axotomy with its absence leading
to fewer TSCs covering the NMJ, abnormalities during regeneration and delayed recovery of motor
function. This study also put forth a non-immune function for MHC class I in axonal regeneration.
Further studies carried out to identify putative MHC class I receptors identified cognate PIR-B receptor,
associated with synaptic plasticity in the CNS and on SCs in the NMJ [25].
Several newer studies in the past 5 years have investigated the potential role of MHC class I in
ALS neurodegeneration. β2m is an essential component that noncovalently associates with MHC
class I and is also expressed in MNs, their axons and promote recovery after nerve axotomy or crush
injuries. Removing β2m from mSOD1 mice considerably shortens disease duration and survival
signifying a positive role for this molecule in regeneration and the disease process [26]. In a rather
elegant study, Nardo et al, compared and contrasted components of the immune system in the NMJs
of slow and fast progressing mSOD1 mice [27]. Indeed, upregulation of immune molecules including
MHC class I and infiltration of peripheral immune CD8+ T cells and macrophages are seen along
motor axons and the NMJ of slow progressing mice but lacking in the fast progressing mice [27]. These
data strongly suggest that activating the immune response around the peripheral nervous system is
crucial to delaying denervation and thereby control disease progression in mSOD1 mice.
2.3. Schwann Cell (SC) Abnormalities and Immune Interactions
Several studies in other areas of neuroscience research have identified key roles for immune
and inflammatory responses in pathology or disruption of normal SC function in peripheral nerve.
Intriguingly, SCs appear to demonstrate many characteristics that directly or indirectly influence
immune interactivity with the peripheral immune system in normal and disease conditions. SCs can
exhibit properties of an immune cell including Ag recognition, presentation, altering local immune
response and termination [28]. T cells exhibit heightened activation in recognition of peptide Ags
in the context of MHC molecules together with co-stimulatory signals from the Ag presenting cell.
In inflammatory nervous system disorders, Schwann cells increase expression of a co-stimulatory
molecule, BB-1, through their maturation toward a myelinating phenotype, though constitutive
expression on immature or non-myelinating SCs could be involved in demyelinating disorders [29].
During NMJ dismantling, axonal retraction and demyelination in ALS, several antigens are likely
presented by SCs that trigger immune responses to promote debris clearance and repair, but also
exacerbate disease progression. Immune involvement in neuroinflammatory conditions could catalyze
physiological changes in the TSC for the initiation of NMJ degeneration and continue throughout the
entire peripheral nerve breakdown process.
In many ways, the responses seen in progressive peripheral nerve pathology is similar between
aged and transgenic ALS animal models. Neuromuscular alterations and disconnections occur,
and glial and neuronal physiology are modified over time. As animals age, research suggests
down-regulation of immune and cytoregulatory functions occur including diminished macrophage
infiltration and SC involvement in myelin debris clearance following nerve injury and repair [30].
As SCs can recruit macrophages via CCL2 release [31], and this release is reduced over time in the
aged nerve, it may be that decreased ability of SCs to recruit macrophages plays a causative role in
this observed response. However, macrophage phagocytic functions also decrease with increased age,
thus, a combination of factors are likely to contribute to these phenomena.
The study of SCs and their potential role in ALS is not new [32–37], however, recent studies have
begun linking neuroinflammatory and immunologic responses to peripheral nerve myelination and SC
function in the disease [27,38]. In addition to MN axons, MHC class I expression is elevated in sciatic
nerve SCs of a C57SOD1G93A mouse model of ALS and coincides with slower disease progression
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compared to faster progressing 129SvSOD1G93A model despite expressing the same amount of mSOD1
transgene [27]. The implications of this finding are that there is enhanced MHC class I recruitment of
CD8+ T cells to the peripheral nerve in the C57SOD1G93A model and the sequela of yet to be recognized
immunologic events involving SCs impacts disease progression and severity. The SCs identified to
show increased MHC class I expression were not located at the NMJ, but rather within the nerve itself
where the cells closely interact with peripheral axons. This evidence is also interesting, as CD8+ T
cells are often associated with cytotoxicity, though their response in this study is associated with less
degeneration and slower disease progression.
In contrast to these findings, a recent study identified a correlation between increased mast cell
infiltration at the extensor digitorum longus (EDL) muscle NMJs and increased paralysis progression in
mSOD1G93A mice [38,39]. This increase in mast cells at the NMJ temporally corresponds with the loss
of TSC coverage and presence at the NMJ in the SOD1 rat. The evidence presented by Trias et al. [38]
suggests mast cells play a role in the NMJ dismantling including TSC retraction as masitinib, a c-kit
tyrosine kinase inhibitor used for mast cell tumors and in neuroinflammatory diseases, diminished
this breakdown of the NMJ in the SOD1 rat in the post-paralysis stage. Based on these findings,
the functional status of the mast cell is important in its role in NMJ pathology as observed in this
experimental model of ALS.
Though ALS is a MN disease, new evidence suggests the SC expression of MHC class II in a
rodent nerve injury model could contribute to sensory hyperalgesia in these animals [40]. Deletion of
MHC class II in myelinating SCs reduced this hyperalgesia, which supports a more complicated role
for Schwann cells in peripheral nerve function in disease or injury conditions. Since peripheral nerves
are often mixed motor and sensory nerves, any effects of motor component dysfunction on sensation
is likely mediated by changes in SC physiology including MHC class II-mediated Ag presentation.
Such a response could at least partially explain the influx of adaptive immune T cells in degenerating
peripheral nerve in ALS. However, this finding is new and whether Schwann cells present Ags to T
cells via MHC class II requires additional study in ALS. Still, the Ag-presentation capacity of SCs raises
many possibilities concerning the neuroimmune involvement of these peripheral myelinating glia in
ALS. Table 1 provides a temporal overview of research related to tissue-specific immune interaction
with neuromuscular components in ALS.
2.4. Skeletal Muscle Immune System Cross-Talk
Progressive weakness and atrophy in skeletal muscles is the cardinal feature of ALS. Skeletal
muscles that are targets of lower MNs, also provide cues for different aspects of NMJ development
and structural maintenance [41]. Thus, in addition to undergoing denervation induced atrophy,
skeletal muscle might also play an active role in NMJ dismantling and the ensuing inflammation
in ALS. Muscle pathology in mSOD1 mice is evident long before MN cell death in the CNS [42].
Interestingly, motor terminal abnormalities are prominent in mSOD1 fast-twitch muscles as early
as post-natal 31–40 days of age, with similar decline in slow-twitch muscles occurring only around
onset of disease symptoms [43]. An increased vulnerability of axons innervating fast-twitch muscles
to degenerate is also observed in ALS patients [44,45]. mSOD1 expression in only skeletal muscle
leads to NMJ abnormalities and muscle pathology largely due to mitochondrial dysfunction and
activation of cell death pathways [46]. Several studies show skeletal muscle as the primary target of
mSOD1-mediated toxicity [47], however, the jury is still out on whether muscular mSOD1 plays a
causal role in MN degeneration.
The role played by peripheral immune cells and molecules on muscle pathology in ALS is only
starting to emerge. Muscle cells express classical Ag presenting molecules, MHC class I and II, either
constitutively at low levels or after exposure to IFN-γ such as in inflammatory muscle diseases [48],
and also express a member of the B7 family of co-stimulatory molecules, ICOSL that is crucial to
fine-tune T-cell responses [49]. Whereas axonal MHC class I expression is attributed to neuroprotection
in ALS, muscular expression of MHC molecules in inflammatory myopathies is usually associated with
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lesion and subsequent atrophy [50,51]. Furthermore, muscle biopsy specimens from inflammatory
myopathy and degenerative muscle disease patients were found to express a non-classical MHC class
I-like molecule called HLA-G [52,53]. HLA-G, a tolerogenic Ag classically studied in maternal-fetal
tolerance, interacts with cytotoxic T lymphocytes and natural killer (NK) cells to mediate tissue
protection from immune-mediated damage [54,55]. Negative co-stimulatory molecules, B7-H1 and
B7-H3, are also markedly increased in muscle fibers from inflammatory myopathies, whereby, via their
strong immune-inhibitory properties, they protect skeletal muscle from immune attack in such
conditions [56,57]. Expression of MHC and positive or negative co-stimulatory molecules enables
muscle cells to act as facultative Ag presenting cells capable of modulating local immune responses,
thereby, warranting characterization of skeletal muscle expression of these molecules at different stages
of ALS disease.
Stressed or dying cells can serve as a source of endogenous danger signals called damage
associated molecular patterns (DAMPs), that can trigger an inflammatory immune response by binding
to a family of innate immune sensors called the Toll-like receptors (TLRs), of which there are 10 in
humans and 13 in mice. TLR signaling is associated with proinflammatory cytokine production and
enhanced Ag presentation to naive T cells, thus it is involved in activation of both innate and adaptive
immune responses [58]. TLRs in CNS glia are capable of being activated by mSOD1 itself, whereby such
activation has been attributed to glia toxicity on one hand [59,60] and on the other, mSOD1 mice lacking
TLR signaling exhibit earlier disease onset and shorter life span [61]. Several findings show expression
of multiple TLRs within skeletal muscle [62–64]. Interestingly, there are more TLR expressing cells
in slow-twitch fibers than fast-twitch muscles in a mouse model of Duchenne muscular dystrophy,
a degenerative myopathy with more muscle pathology in fast-twitch muscles like that observed in
ALS [65]. However, due to technical challenges, it was difficult to correlate TLR expression levels
with the extent of muscle damage in that study. Nonetheless, spatial differences in TLR expression
could impact the downstream cytokine/chemokine response and ongoing inflammation. Targeting
TLRs as a treatment modality is being actively pursued in ALS [66,67]; therefore, characterizing
specific TLR pathways involved in neurotoxicity and muscle pathology will be crucial in recognizing
targets for altering local immune responses. Another class of majorly studied innate immune molecules
implicated in ALS disease are the complement proteins. Numerous studies have identified components
of the complement pathways to be upregulated in the serum, cerebrospinal fluid, spinal cord and motor
cortex of ALS patients and mSOD1 mice [68–71]. In line with the dying back hypothesis, a study shows
complement activation products C3/C3b and C1q in motor end plates of mSOD1 mice by postnatal day
47 around the same time that NMJ denervation begins [72,73]. It is possible that similar to elimination
of synapses during development [74], complement proteins play a role in NMJ degeneration in ALS.
Another recent supports this hypothesis by data showing dysregulation of terminal complement
protein C5a-C5aR1 signaling axis within skeletal muscle leading to chronic accumulation of peripheral
macrophages that switches them to inflammatory phenotype and exacerbate muscle damage [75].
In response to injury or damage, the skeletal muscle can act as a local source of immune mediators
by releasing proinflammatory cytokines (IL-6, IL-8), chemokines (RANTES, MCP-1) and express
surface molecules (ICAM-1) that can exert autocrine and paracrine effects allowing recruitment of
neutrophils, macrophages and adaptive immune T cells into the damaged muscle [76–78]. In addition,
studies in acute injury models highlight the importance of muscle resident immune cells including
CD8+ cytotoxic T cells, regulatory T (Treg) cells, neutrophils and eosinophils in not just the immediate
response to injury but also by producing inflammatory cytokines, IFN-γ and TNF-α, they regulate
key transcription factors in myogenic precursor satellite cells involved in repair and regeneration [79].
Muscle resident fibro/adipocyte progenitors (FAPs), bipotent cells capable of giving rise to fibroblasts
or adipocytes, are in close association with regenerating muscle fibers and control the balance between
muscle regeneration and fatty degeneration. Interestingly, eosinophil-derived, anti-inflammatory
cytokines, IL-4 and IL-13, are critical for FAPs to promote muscle regeneration primarily, through
blocking their adipogenic differentiation, enhanced proliferation and debris clearance in the injured
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muscle [80]. Although, the role of eosinophils in ALS has not been directly investigated, elevated
levels of eosinophil-derived neurotoxin and RANTES, a chemokine factor for eosinophils in serum
and histological evidence in skeletal muscle biopsies from ALS patients is documented [81–83].
Also, peripheral nerves can produce eosinophil chemotactic factors and adhesion molecules to promote
their recruitment upon which, eosinophils potentially cause axonal damage of MNs via release of
neuronal reactive oxygen species and toxic proteins [84–86]. Taken together, these studies emphasize
the need for a more direct approach such as crossing the eosinophil-deficient ∆dblGATA mice to the
mSOD1ALS mice to investigate the role of eosinophils in ALS disease both at the CNS and at the
NMJ [87].
Potent suppressors of immune responses, the CD4+ T regulatory cells (Tregs), also work to
maintain tissue homeostasis in non-immune organs, including injured and regenerating skeletal
muscle. Skeletal muscle Tregs are a phenotypically and functionally distinct population characterized
by their signature expression of IL-33 cytokine receptor, ST2 and growth factor amphiregulin (Areg).
These cells accumulate around the time when infiltrating myeloid cells switch from proinflammatory
to a regenerative phenotype [88]. An interesting study of acute muscle injury in aged mice uncovered
an unexpected role for nerve-associated FAPs as IL-33 producers, the ligand for the Treg ST2; with
there being reduced IL-33 production in skeletal muscle from aged mice [89]. Thus, this study
suggests an important role for the IL-33:ST2 axis for muscle Treg accumulation and regeneration.
Sera from ALS patients were found to have significantly reduced levels of IL-33 levels and elevated
levels of soluble ST2 receptors relative to healthy controls [90]. In another study, IL-33 released by
oligodendrocytes and astrocytes after CNS injury works with yet-to-be identified factors to steer
macrophages towards an anti-inflammatory, pro-regenerative M2 phenotype [91]. Targeting IL-33 to
improve disease outcome has been promising in other neurodegenerative diseases such as experimental
autoimmune encephalomyelitis (EAE) and Alzheimer’s [92,93]; therefore, investigating the IL-33:ST2
axis in skeletal muscle pathology and glial toxicity in ALS might be beneficial.
Another immunoregulatory cytokine expressed by muscle cells in inflammatory myopathies is
IL-15. IL-15 expression by skeletal muscle promotes increased cytotoxicity and effector function of
CD8+ T cells leading to disease progression in autoimmune myositis [94]. IL-15 is a crucial cytokine
for NK cell development, survival and function; both soluble and membrane-bound IL-15/IL-15Rα
complexes increase stability of IL-15 and can effectively activate NK cells even at distant sites via a
unique, novel ‘trans-presentation’ mechanism of signal transduction. A drop in NK cell numbers with
aging is concurrent with declining levels and stability of skeletal muscle IL-15 in aged mice [95]. In ALS,
serum IL-15 levels are elevated although there is no correlation with disease onset or duration [96].
Interestingly, in a recent peripheral blood immunophenotyping study, ALS patients also exhibit
elevated NK cell counts that inversely correlates with the ALSFRS-R score [97]. In contrast to the
suggested molecular parallels in aging and ALS [98,99], IL-15 and NK cell levels are elevated in ALS
opposite to their decline in aging. NK cells are neuroprotective via their production of neurotrophic
factors such as BDNF, NT-3 in EAE [100] and play deleterious roles in other neurodegenerative diseases
such as MS and Alzheimer’s [101,102]. Thus, discovering the role of IL-15/NK cell axis in CNS and
NMJ microenvironments of mSOD1 mice can help develop IL-15/NK-cell based therapies for ALS.
Skeletal muscle is a promising target tissue to alter the local and systemic immune response in ALS,
due to the tissue abundance, easy accessibility and extensive studies on its immune system interactions
in vaccine biology. Although transcriptomics analysis of immune markers in ALS skeletal muscle is
emerging [103], direct investigation of skeletal muscle-driven immune responses in ALS are currently
limited. A detailed study on skeletal muscle-driven immune responses in mSOD1 mice might result in
development of cellular immunotherapies or immune-target based interventions for treating ALS.
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Table 1. Temporospatial breakdown of observed immune interactions in ALS.
Reported Immune Cellular/Marker
Changes in ALS ALS Model
Earliest Observed Immune System
Changes in Postnatal Days of Age Reference(s)
Increased lymphocyte cell numbers in
spinal cord and altered microglial
immune profile
B6SJL.SOD1G93A 65 (presymptomatic) [12]
Reduced growth factors and increased
neurotoxic molecular expression in the
absence of CD4+ T cells
B6.SOD1G93A ~180 (end-stage) [13]
Increase in percent CD4+CD25+,
CD25+FoxP3 Tregs in SOD1 mice blood
and reduced Tregs in ALS patients with
rapidly progressing disease
B6.SOD1G93A and definite or
probable sporadic ALS patients
77 (symptom onset), peak at 112
(stable disease phase) in mice [14]
Increased β2m in spinal cord of ALS mice B6.SOD1G93A 130 (mid-symptomatic) [26]
Increase in MHC class I, β2m, LMP7,
CCL2, C3, macrophages and CD8+ T cells
along axons of peripheral nerve; MHC
class I overlap with Schwann cells
B6.SOD1G93A 135 (mid-symptomatic) [27]
Endomysial infiltration of mast cells SOD1
G93A rats
NTac:SD-Tg(SOD1G93A) L26H
Paralysis onset (187+/−15) [38,39]
C3 activation products, C1q in motor end
plates in mice; C1q and regulators CD55,
CD59 on motor end plates in
intercostal muscle
B6SJL.SOD1G93A; sporadic and
familial ALS patients
47 (presymptomatic); post-mortem [72,73]
C1qB, C4, fB, C3, C5a, and C5aR1 in
tibialis anterior (TA) muscles; C5a and its
receptor C5aR1 in TA and soleus muscle
with C5aR1 localization on macrophages
B6.SOD1G93A
Variable between 77 (symptom
onset) and 130 (mid-symptomatic)
for each listed molecule, however,
most molecules are upregulated by
77; at 77 (symptom onset)
[75]
Elevated eosinophil-derived neurotoxin
in serum and chemokine RANTES in
serum and CSF
ALS patients Mean ALSFRS-R = 17.8 (SD = 13.29) [81,82]
Reduced IL-33 and elevated levels of
soluble ST2 receptors in serum ALS patients
met the modified El Escorial criteria
for probable or definite ALS [90]
Elevated serum IL-15 and NK cells ALS patients - [96,97]
Increased macrophage accumulation in
sciatic nerve, T cell co-stimulatory
pathway upregulated in skeletal muscle,
sciatic nerve, spinal cord and in blood
samples from ALS patients
B6SJL.SOD1G93A and
ALS patients
50 (symptom onset) through 120
(end-stage) in mice [103]
3. Conclusions
Research in available animal models has identified key aspects of the temporospatial progression
and immune system involvement in neuromuscular breakdown in ALS (Table 1, Figures 2 and 3) [104].
Though such models are not perfect, they have advanced our understanding of complex neuroimmune
interactions that also occur in ALS patients. Systemic immune system activation in ALS has also
been identified in addition to those at the CNS and PNS, including an increased ratio of neutrophils
and monocytes [105], an inflammatory phenotype of circulating dendritic cells [106], and lower Tregs
and Foxp3 expression [107]. Such examples highlight the importance of understanding the impact
of systemic immune changes in modulating tissue specific disease pathways discussed in the above
sections. Further research is necessary to link systemic and localized immune responses in sporadic
and familial forms of ALS. Studies thus far on immune-associated therapies for ALS patients have
emphasized the non-cell autonomous nature of the disease and the inflammatory component within
the CNS microenvironment. Specifically, the inflammatory regulation in the CNS relies heavily
on the activation state of astrocytes and microglia and communication with the systemic immune
response, and though targeting neuroinflammation with various compounds have worked in animal
models, the beneficial results have not translated to humans. Drugs including celecoxib and TNF-α
inhibitor thalidomide, [108,109] have not showed significant benefits when used clinically to treat ALS.
Immunotherapies including corticosteroids, cyclophosphamide, and cyclosporine have also not shown
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promising results in clinical treatment of ALS [110,111]. Reasons for this, as summarized by Crisafulli
et al. [112] may be due to the delayed time points of delivery during advanced disease stages. One of
the problems with many therapies for ALS in humans is that therapy is administered once the disease
is diagnosed, and at this point perhaps the disease has progressed beyond the ability to slow or reverse
neurodegeneration and subsequent functional decline and paralysis.
Int. J. Mol. Sci. 2018, 19, x 10 of 16 
 
 
Figure 3. Schematic illustration summarizing peripheral nerve components and immune system 
involvement in degeneration and pathology. 
Despite our expanding understanding of cellular and physiological contributors to ALS onset 
and progression, there is still much to learn and identifying such processes and stages in human ALS 
is difficult. Therefore, improving our ability for early detection of the disease by identifying specific 
biomarkers that indicate temporospatial state of disease and immunologic and inflammatory 
correlates with these markers is essential for the best assessment of the efficacy of the variety of 
clinically-approved and newly developed immune and inflammation-targeted therapies. Also, new 
animal models that more widely represent the true ALS patient population beyond mutant SOD1 
and other hereditary minority subsets of the disease would likely aid in screening such therapies 
before advancing to human application. 
Though recent research has expanded our understanding of the role of the immune response in 
MN diseases such as ALS, this review highlights not only new findings that contribute to this 
understanding, but also gaps in knowledge that still remain. ALS is considered a non-cell 
autonomous disease, as we now know many non-neuronal nervous system cells contribute to 
pathology, including astrocytes, microglia and neuromuscular interactions. We have focused on 
highlighting how complex immune system involvement may be in predicting the motor function 
outcome in this debilitating disease. It will be key for future research to connect findings involving 
immune involvement in CNS cell responses to those that reside in the peripheral segment: Schwann 
cells, fibroblasts, muscle cells, etc. Such investigations hold tremendous promise in identifying 
patterns to characterize immune responses at different disease phases that lead not only to potential 
therapeutic targets, but also biomarkers to improve speed of diagnosis. 
Acknowledgments: This work was supported by NIH T32 HL79995 post-doctoral training fellowship (Chandler 
L. Walker), Indiana University Collaborative Research Grant and NIH/NINDS R01 funding NS40433 (Kathryn 
J. Jones). 
Conflicts of Interest: The authors declare no conflict of interest. 
References 
1. Talbot, K. Motor neuron disease: The bare essentials. Pract. Neurol. 2009, 9, 303–309. 
2. Petrov, D.; Mansfield, C.; Moussy, A.; Hermine, O. ALS clinical trials review: 20 years of failure. Are we 
any closer to registering a new treatment? Front. Aging Neurosci. 2017, 9, 68. 
Figure 3. Schematic illustration summarizing peripheral nerve components and immune system
involvement in degeneration and pathology.
Despite our expanding understanding of cellular and physiological contributors to ALS onset
and progression, there is still much to learn nd identifying such pr cesses a d stages in human
ALS is difficult. Therefore, improving our ability for early detection of the disease by identifying
specific biomarkers that indicate temporospatial state of disease and immunologic and inflammatory
correlates with these markers is essential for the best assessment of the efficacy of the variety of
clinically-app oved and newly developed immune and inflammation-targeted therapies. Also, new
animal models that more widely represent the true ALS patient population beyond mutant SOD1 and
other hereditary minority subsets of the disease would likely aid in screening such therapies before
advancing to human application.
Though recent research has expanded our understanding of the role of the immune response
in MN diseases such as ALS, this review highlights not only new findings that contribute to this
understanding, but also gaps in knowledge that still remain. ALS is considered a non-cell autonomous
disease, as we now know many non-neuronal nervous system cells contribute to pathology, including
astrocytes, microglia nd neuro scular interactions. We have focused on highlighting how complex
immune system involvement may be in predicting the motor function outcome in this debilitating
disease. It will be key for future research to connect findings inv lving immune involvement in CNS
cell responses to those that reside in the peripheral segment: Schwann cells, fibroblasts, muscle cells, etc.
Such investigations hold tremendous promise in identifying patterns to characterize immune responses
at different disease phases that lead not only to potential therapeutic targets, but also biomarkers to
improve sp ed of diagnosis.
Acknowledgments: This work was supported by NIH T32 HL79995 post-doctoral training fellowship
(Chandler L. Walker), Indiana University Collaborative Research Grant and NIH/NINDS R01 funding NS40433
(Kathryn J. Jones).
Conflicts of Interest: The authors declare no conflict of interest.
Int. J. Mol. Sci. 2018, 19, 631 11 of 16
References
1. Talbot, K. Motor neuron disease: The bare essentials. Pract. Neurol. 2009, 9, 303–309. [CrossRef] [PubMed]
2. Petrov, D.; Mansfield, C.; Moussy, A.; Hermine, O. ALS clinical trials review: 20 years of failure. Are we any
closer to registering a new treatment? Front. Aging Neurosci. 2017, 9, 68. [CrossRef] [PubMed]
3. Philips, T.; Rothstein, J.D. Rodent models of amyotrophic lateral sclerosis. Curr. Protoc. Pharmacol. 2015.
[CrossRef]
4. Kraemer, M.; Buerger, M.; Berlit, P. Diagnostic problems and delay of diagnosis in amyotrophic lateral
sclerosis. Clin. Neurol. Neurosurg. 2010, 112, 103–105. [CrossRef] [PubMed]
5. Fischer, L.R.; Culver, D.G.; Tennant, P.; Davis, A.A.; Wang, M.; Castellano-Sanchez, A.; Khan, J.; Polak, M.A.;
Glass, J.D. Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp. Neurol.
2004, 185, 232–240. [CrossRef] [PubMed]
6. Puentes, F.; Topping, J.; Kuhle, J.; van der Star, B.J.; Douiri, A.; Giovannoni, G.; Baker, D.; Amor, S.;
Malaspina, A. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral
sclerosis. J. Neurol. Neurosurg. Psychiatry 2014, 85, 274–278. [CrossRef] [PubMed]
7. Malaspina, A.; Puentes, F.; Amor, S. Disease origin and progression in amyotrophic lateral sclerosis:
An immunology perspective. Int. Immunol. 2015, 27, 117–129. [CrossRef] [PubMed]
8. Ilieva, H.; Polymenidou, M.; Cleveland, D.W. Non-cell autonomous toxicity in neurodegenerative disorders:
ALS and beyond. J. Cell Biol. 2009, 187, 761–772. [CrossRef] [PubMed]
9. Beers, D.R.; Henkel, J.S.; Xiao, Q.; Zhao, W.; Wang, J.; Yen, A.A.; Siklos, L.; McKercher, S.R.; Appel, S.H.
Wild-type microglia extend survival in pu.1 knockout mice with familial amyotrophic lateral sclerosis.
Proc. Natl. Acad. Sci. USA 2006, 103, 16021–16026. [CrossRef] [PubMed]
10. Yamanaka, K.; Chun, S.J.; Boillee, S.; Fujimori-Tonou, N.; Yamashita, H.; Gutmann, D.H.; Takahashi, R.;
Misawa, H.; Cleveland, D.W. Astrocytes as determinants of disease progression in inherited amyotrophic
lateral sclerosis. Nat. Neurosci. 2008, 11, 251–253. [CrossRef] [PubMed]
11. Rossi, S.; Cozzolino, M.; Carri, M.T. Old versus new mechanisms in the pathogenesis of ALS. Brain Pathol.
2016, 26, 276–286. [CrossRef] [PubMed]
12. Chiu, I.M.; Chen, A.; Zheng, Y.; Kosaras, B.; Tsiftsoglou, S.A.; Vartanian, T.K.; Brown, R.H., Jr.; Carroll, M.C.
T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl.
Acad. Sci. USA 2008, 105, 17913–17918. [CrossRef] [PubMed]
13. Beers, D.R.; Henkel, J.S.; Zhao, W.; Wang, J.; Appel, S.H. CD4+ T cells support glial neuroprotection, slow
disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad.
Sci. USA 2008, 105, 15558–15563. [CrossRef] [PubMed]
14. Beers, D.R.; Henkel, J.S.; Zhao, W.; Wang, J.; Huang, A.; Wen, S.; Liao, B.; Appel, S.H. Endogenous regulatory
T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in
patients with amyotrophic lateral sclerosis. Brain 2011, 134, 1293–1314. [CrossRef] [PubMed]
15. Rothstein, D.M.; Camirand, G. New insights into the mechanisms of Treg function. Curr. Opin.
Organ Transplant. 2015, 20, 376–384. [CrossRef] [PubMed]
16. Deboy, C.A.; Xin, J.; Byram, S.C.; Serpe, C.J.; Sanders, V.M.; Jones, K.J. Immune-mediated neuroprotection of
axotomized mouse facial motoneurons is dependent on the IL-4/STAT6 signaling pathway in CD4+ T cells.
Exp. Neurol. 2006, 201, 212–224. [CrossRef] [PubMed]
17. Setter, D.O.; Runge, E.M.; Schartz, N.D.; Kennedy, F.M.; Brown, B.L.; McMillan, K.P.; Miller, W.M.; Shah, K.M.;
Haulcomb, M.M.; Sanders, V.M.; et al. Impact of peripheral immune status on central molecular responses
to facial nerve axotomy. Brain Behav. Immun. 2017. [CrossRef] [PubMed]
18. Endo, F.; Komine, O.; Fujimori-Tonou, N.; Katsuno, M.; Jin, S.; Watanabe, S.; Sobue, G.; Dezawa, M.;
Wyss-Coray, T.; Yamanaka, K. Astrocyte-derived TGF-β1 accelerates disease progression in ALS mice by
interfering with the neuroprotective functions of microglia and T cells. Cell Rep. 2015, 11, 592–604. [CrossRef]
[PubMed]
19. Song, S.; Miranda, C.J.; Braun, L.; Meyer, K.; Frakes, A.E.; Ferraiuolo, L.; Likhite, S.; Bevan, A.K.; Foust, K.D.;
McConnell, M.J.; et al. Major histocompatibility complex class I molecules protect motor neurons from
astrocyte-induced toxicity in amyotrophic lateral sclerosis. Nat. Med. 2016, 22, 397–403. [CrossRef] [PubMed]
20. Li, L.; Xiong, W.C.; Mei, L. Neuromuscular junction formation, aging, and disorders. Annu. Rev. Physiol.
2017, 80, 159–188. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 631 12 of 16
21. Oliveira, A.L.; Thams, S.; Lidman, O.; Piehl, F.; Hokfelt, T.; Karre, K.; Linda, H.; Cullheim, S. A role for MHC
class I molecules in synaptic plasticity and regeneration of neurons after axotomy. Proc. Natl. Acad. Sci. USA
2004, 101, 17843–17848. [CrossRef] [PubMed]
22. Stevens, B.; Allen, N.J.; Vazquez, L.E.; Howell, G.R.; Christopherson, K.S.; Nouri, N.; Micheva, K.D.;
Mehalow, A.K.; Huberman, A.D.; Stafford, B.; et al. The classical complement cascade mediates CNS synapse
elimination. Cell 2007, 131, 1164–1178. [CrossRef] [PubMed]
23. Thams, S.; Oliveira, A.; Cullheim, S. MHC class I expression and synaptic plasticity after nerve lesion.
Brain Res. Rev. 2008, 57, 265–269. [CrossRef] [PubMed]
24. Maehlen, J.; Nennesmo, I.; Olsson, A.B.; Olsson, T.; Schroder, H.D.; Kristensson, K. Peripheral nerve injury
causes transient expression of MHC class I antigens in rat motor neurons and skeletal muscles. Brain Res.
1989, 481, 368–372. [CrossRef]
25. Thams, S.; Brodin, P.; Plantman, S.; Saxelin, R.; Karre, K.; Cullheim, S. Classical major histocompatibility
complex class I molecules in motoneurons: New actors at the neuromuscular junction. J. Neurosci. 2009, 29,
13503–13515. [CrossRef] [PubMed]
26. Staats, K.A.; Schonefeldt, S.; Van Rillaer, M.; Van Hoecke, A.; Van Damme, P.; Robberecht, W.; Liston, A.;
Van Den Bosch, L. B-2 microglobulin is important for disease progression in a murine model for amyotrophic
lateral sclerosis. Front. Cell. Neurosci. 2013, 7, 249. [CrossRef] [PubMed]
27. Nardo, G.; Trolese, M.C.; de Vito, G.; Cecchi, R.; Riva, N.; Dina, G.; Heath, P.R.; Quattrini, A.; Shaw, P.J.;
Piazza, V.; et al. Immune response in peripheral axons delays disease progression in SOD1 G93A mice.
J. Neuroinflamm. 2016, 13, 261. [CrossRef] [PubMed]
28. Meyer zu Horste, G.; Hu, W.; Hartung, H.P.; Lehmann, H.C.; Kieseier, B.C. The immunocompetence of
schwann cells. Muscle Nerve 2008, 37, 3–13. [CrossRef] [PubMed]
29. Murata, K.; Dalakas, M.C. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28
and their mRNAs in chronic inflammatory demyelinating polyneuropathy. Brain 2000, 123, 1660–1666.
[CrossRef] [PubMed]
30. Painter, M.W. Aging Schwann cells: Mechanisms, implications, future directions. Curr. Opin. Neurobiol. 2017,
47, 203–208. [CrossRef] [PubMed]
31. Toews, A.D.; Barrett, C.; Morell, P. Monocyte chemoattractant protein 1 is responsible for macrophage
recruitment following injury to sciatic nerve. J. Neurosci. Res. 1998, 53, 260–267. [CrossRef]
32. Turner, B.J.; Ackerley, S.; Davies, K.E.; Talbot, K. Dismutase-competent SOD1 mutant accumulation in
myelinating Schwann cells is not detrimental to normal or transgenic ALS model mice. Hum. Mol. Genet.
2010, 19, 815–824. [CrossRef] [PubMed]
33. Lobsiger, C.S.; Boillee, S.; McAlonis-Downes, M.; Khan, A.M.; Feltri, M.L.; Yamanaka, K.; Cleveland, D.W.
Schwann cells expressing dismutase active mutant SOD1 unexpectedly slow disease progression in ALS
mice. Proc. Natl. Acad. Sci. USA 2009, 106, 4465–4470. [CrossRef] [PubMed]
34. Wang, L.; Pytel, P.; Feltri, M.L.; Wrabetz, L.; Roos, R.P. Selective knockdown of mutant SOD1 in Schwann
cells ameliorates disease in G85R mutant SOD1 transgenic mice. Neurobiol. Dis. 2012, 48, 52–57. [CrossRef]
[PubMed]
35. Arbour, D.; Vande Velde, C.; Robitaille, R. New perspectives on amyotrophic lateral sclerosis: The role of
glial cells at the neuromuscular junction. J. Physiol. 2017, 595, 647–661. [CrossRef] [PubMed]
36. Carrasco, D.I.; Seburn, K.L.; Pinter, M.J. Altered terminal Schwann cell morphology precedes denervation in
SOD1 mice. Exp. Neurol. 2016, 275, 172–181. [CrossRef] [PubMed]
37. Carrasco, D.I.; Bahr, B.A.; Seburn, K.L.; Pinter, M.J. Abnormal response of distal Schwann cells to denervation
in a mouse model of motor neuron disease. Exp. Neurol. 2016, 278, 116–126. [CrossRef] [PubMed]
38. Trias, E.; Ibarburu, S.; Barreto-Nunez, R.; Varela, V.; Moura, I.C.; Dubreuil, P.; Hermine, O.; Beckman, J.S.;
Barbeito, L. Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS.
JCI Insight 2017, 2, 20. [CrossRef] [PubMed]
39. Trias, E.; Ibarburu, S.; Barreto-Nunez, R.; Babdor, J.; Maciel, T.T.; Guillo, M.; Gros, L.; Dubreuil, P.;
Diaz-Amarilla, P.; Cassina, P.; et al. Post-paralysis tyrosine kinase inhibition with masitinib abrogates
neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J. Neuroinflamm.
2016, 13, 177. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 631 13 of 16
40. Hartlehnert, M.; Derksen, A.; Hagenacker, T.; Kindermann, D.; Schafers, M.; Pawlak, M.; Kieseier, B.C.;
Meyer Zu Horste, G. Schwann cells promote post-traumatic nerve inflammation and neuropathic pain
through MHC class Ii. Sci. Rep. 2017, 7, 12518. [CrossRef] [PubMed]
41. Burden, S.J.; Yumoto, N.; Zhang, W. The role of MuSK in synapse formation and neuromuscular disease.
Cold Spring Harb. Perspect. Biol. 2013, 5, a009167. [CrossRef] [PubMed]
42. Marcuzzo, S.; Zucca, I.; Mastropietro, A.; de Rosbo, N.K.; Cavalcante, P.; Tartari, S.; Bonanno, S.; Preite, L.;
Mantegazza, R.; Bernasconi, P. Hind limb muscle atrophy precedes cerebral neuronal degeneration in
G93A-SOD1 mouse model of amyotrophic lateral sclerosis: A longitudinal MRI study. Exp. Neurol. 2011, 231,
30–37. [CrossRef] [PubMed]
43. Hegedus, J.; Putman, C.T.; Gordon, T. Time course of preferential motor unit loss in the SOD1 G93A mouse
model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2007, 28, 154–164. [CrossRef] [PubMed]
44. Dengler, R.; Konstanzer, A.; Kuther, G.; Hesse, S.; Wolf, W.; Struppler, A. Amyotrophic lateral sclerosis:
Macro-EMG and twitch forces of single motor units. Muscle Nerve 1990, 13, 545–550. [CrossRef] [PubMed]
45. Sanjak, M.; Brinkmann, J.; Belden, D.S.; Roelke, K.; Waclawik, A.; Neville, H.E.; Ringel, S.P.; Murphy, J.R.;
Brooks, B.R. Quantitative assessment of motor fatigue in amyotrophic lateral sclerosis. J. Neurol. Sci. 2001,
191, 55–59. [CrossRef]
46. Wong, M.; Martin, L.J. Skeletal muscle-restricted expression of human SOD1 causes motor neuron
degeneration in transgenic mice. Hum. Mol. Genet. 2010, 19, 2284–2302. [CrossRef] [PubMed]
47. Dobrowolny, G.; Aucello, M.; Rizzuto, E.; Beccafico, S.; Mammucari, C.; Boncompagni, S.; Belia, S.;
Wannenes, F.; Nicoletti, C.; Del Prete, Z.; et al. Skeletal muscle is a primary target of SOD1G93A-mediated
toxicity. Cell Metab. 2008, 8, 425–436. [CrossRef] [PubMed]
48. Garlepp, M.J.; Chen, W.; Tabarias, H.; Baines, M.; Brooks, A.; McCluskey, J. Antigen processing and
presentation by a murine myoblast cell line. Clin. Exp. Immunol. 1995, 102, 614–619. [CrossRef] [PubMed]
49. Wiendl, H.; Mitsdoerffer, M.; Schneider, D.; Melms, A.; Lochmuller, H.; Hohlfeld, R.; Weller, M. Muscle fibres
and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: Implications
for the pathogenesis of inflammatory myopathies. Brain 2003, 126, 1026–1035. [CrossRef] [PubMed]
50. Das, L.; Blumbergs, P.C.; Manavis, J.; Limaye, V.S. Major histocompatibility complex class I and II expression
in idiopathic inflammatory myopathy. Appl. Immunohistochem. Mol. Morphol. 2013, 21, 539–542. [CrossRef]
[PubMed]
51. Englund, P.; Lindroos, E.; Nennesmo, I.; Klareskog, L.; Lundberg, I.E. Skeletal muscle fibers express major
histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory
myopathies. Am. J. Pathol. 2001, 159, 1263–1273. [CrossRef]
52. Wiendl, H.; Behrens, L.; Maier, S.; Johnson, M.A.; Weiss, E.H.; Hohlfeld, R. Muscle fibers in inflammatory
myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G.
Ann. Neurol. 2000, 48, 679–684. [CrossRef]
53. Wiendl, H.; Mitsdoerffer, M.; Weller, M. Express and protect yourself: The potential role of HLA-G on muscle
cells and in inflammatory myopathies. Hum. Immunol. 2003, 64, 1050–1056. [CrossRef] [PubMed]
54. Rouas-Freiss, N.; Goncalves, R.M.; Menier, C.; Dausset, J.; Carosella, E.D. Direct evidence to support the role
of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc. Natl. Acad. Sci. USA
1997, 94, 11520–11525. [CrossRef] [PubMed]
55. Riteau, B.; Rouas-Freiss, N.; Menier, C.; Paul, P.; Dausset, J.; Carosella, E.D. HLA-G2, -G3, and -G4 isoforms
expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTl cytolysis. J. Immunol.
2001, 166, 5018–5026. [CrossRef] [PubMed]
56. Wiendl, H.; Mitsdoerffer, M.; Schneider, D.; Chen, L.; Lochmuller, H.; Melms, A.; Weller, M. Human muscle
cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: A novel
mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J. 2003,
17, 1892–1894. [CrossRef] [PubMed]
57. Waschbisch, A.; Wintterle, S.; Lochmuller, H.; Walter, M.C.; Wischhusen, J.; Kieseier, B.C.; Wiendl, H. Human
muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions.
Arthritis Rheum. 2008, 58, 3600–3608. [CrossRef] [PubMed]
58. Kawasaki, T.; Kawai, T. Toll-like receptor signaling pathways. Front. Immunol. 2014, 5, 461. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2018, 19, 631 14 of 16
59. Zhao, W.; Beers, D.R.; Henkel, J.S.; Zhang, W.; Urushitani, M.; Julien, J.P.; Appel, S.H. Extracellular mutant
SOD1 induces microglial-mediated motoneuron injury. Glia 2010, 58, 231–243. [CrossRef] [PubMed]
60. Nguyen, M.D.; D’Aigle, T.; Gowing, G.; Julien, J.P.; Rivest, S. Exacerbation of motor neuron disease by
chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2004,
24, 1340–1349. [CrossRef] [PubMed]
61. Kang, J.; Rivest, S. MyD88-deficient bone marrow cells accelerate onset and reduce survival in a mouse
model of amyotrophic lateral sclerosis. J. Cell Biol. 2007, 179, 1219–1230. [CrossRef] [PubMed]
62. Warren, G.L.; Hulderman, T.; Liston, A.; Simeonova, P.P. Toll-like and adenosine receptor expression in
injured skeletal muscle. Muscle Nerve 2011, 44, 85–92. [CrossRef] [PubMed]
63. Schreiner, B.; Voss, J.; Wischhusen, J.; Dombrowski, Y.; Steinle, A.; Lochmuller, H.; Dalakas, M.; Melms, A.;
Wiendl, H. Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly
expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands.
FASEB J. 2006, 20, 118–120. [CrossRef] [PubMed]
64. Pillon, N.J.; Krook, A. Innate immune receptors in skeletal muscle metabolism. Exp. Cell Res. 2017, 360,
47–54. [CrossRef] [PubMed]
65. Henriques-Pons, A.; Yu, Q.; Rayavarapu, S.; Cohen, T.V.; Ampong, B.; Cha, H.J.; Jahnke, V.; Van der Meulen, J.;
Wang, D.; Jiang, W.; et al. Role of toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and
heart muscle. Hum. Mol. Genet. 2014, 23, 2604–2617. [CrossRef] [PubMed]
66. Fellner, A.; Barhum, Y.; Angel, A.; Perets, N.; Steiner, I.; Offen, D.; Lev, N. Toll-like receptor-4 inhibitor
TAK-242 attenuates motor dysfunction and spinal cord pathology in an amyotrophic lateral sclerosis mouse
model. Int. J. Mol. Sci. 2017, 18. [CrossRef] [PubMed]
67. Letiembre, M.; Liu, Y.; Walter, S.; Hao, W.; Pfander, T.; Wrede, A.; Schulz-Schaeffer, W.; Fassbender, K.
Screening of innate immune receptors in neurodegenerative diseases: A similar pattern. Neurobiol. Aging
2009, 30, 759–768. [CrossRef] [PubMed]
68. Sta, M.; Sylva-Steenland, R.M.; Casula, M.; de Jong, J.M.; Troost, D.; Aronica, E.; Baas, F. Innate and adaptive
immunity in amyotrophic lateral sclerosis: Evidence of complement activation. Neurobiol. Dis. 2011, 42,
211–220. [CrossRef] [PubMed]
69. Ferraiuolo, L.; Heath, P.R.; Holden, H.; Kasher, P.; Kirby, J.; Shaw, P.J. Microarray analysis of the cellular
pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse
model of familial ALS. J. Neurosci. 2007, 27, 9201–9219. [CrossRef] [PubMed]
70. Lobsiger, C.S.; Boillee, S.; Cleveland, D.W. Toxicity from different SOD1 mutants dysregulates the
complement system and the neuronal regenerative response in ALS motor neurons. Proc. Natl. Acad.
Sci. USA 2007, 104, 7319–7326. [CrossRef] [PubMed]
71. Woodruff, T.M.; Costantini, K.J.; Crane, J.W.; Atkin, J.D.; Monk, P.N.; Taylor, S.M.; Noakes, P.G.
The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis.
J. Immunol. 2008, 181, 8727–8734. [CrossRef] [PubMed]
72. Heurich, B.; El Idrissi, N.B.; Donev, R.M.; Petri, S.; Claus, P.; Neal, J.; Morgan, B.P.; Ramaglia, V. Complement
upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model
of familial amyotrophic lateral sclerosis. J. Neuroimmunol. 2011, 235, 104–109. [CrossRef] [PubMed]
73. Bahia El Idrissi, N.; Bosch, S.; Ramaglia, V.; Aronica, E.; Baas, F.; Troost, D. Complement activation at the
motor end-plates in amyotrophic lateral sclerosis. J. Neuroinflamm. 2016, 13, 72. [CrossRef] [PubMed]
74. Presumey, J.; Bialas, A.R.; Carroll, M.C. Complement system in neural synapse elimination in development
and disease. Adv. Immunol. 2017, 135, 53–79. [PubMed]
75. Wang, H.A.; Lee, J.D.; Lee, K.M.; Woodruff, T.M.; Noakes, P.G. Complement C5a-C5aR1 signalling drives
skeletal muscle macrophage recruitment in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis.
Skelet. Muscle 2017, 7, 10. [CrossRef] [PubMed]
76. Figarella-Branger, D.; Civatte, M.; Bartoli, C.; Pellissier, J.F. Cytokines, chemokines, and cell adhesion
molecules in inflammatory myopathies. Muscle Nerve 2003, 28, 659–682. [CrossRef] [PubMed]
77. Jain, A.; Sharma, M.C.; Sarkar, C.; Bhatia, R.; Singh, S.; Handa, R. Increased expression of cell adhesion
molecules in inflammatory myopathies: Diagnostic utility and pathogenetic insights. Folia Neuropathol. 2009,
47, 33–42. [PubMed]
78. Peake, J.M.; Della Gatta, P.; Suzuki, K.; Nieman, D.C. Cytokine expression and secretion by skeletal muscle
cells: Regulatory mechanisms and exercise effects. Exerc. Immunol. Rev. 2015, 21, 8–25. [PubMed]
Int. J. Mol. Sci. 2018, 19, 631 15 of 16
79. Tidball, J.G. Regulation of muscle growth and regeneration by the immune system. Nat. Rev. Immunol. 2017,
17, 165–178. [CrossRef] [PubMed]
80. Heredia, J.E.; Mukundan, L.; Chen, F.M.; Mueller, A.A.; Deo, R.C.; Locksley, R.M.; Rando, T.A.; Chawla, A.
Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell 2013, 153,
376–388. [CrossRef] [PubMed]
81. Liu, G.T.; Hwang, C.S.; Hsieh, C.H.; Lu, C.H.; Chang, S.L.; Lee, J.C.; Huang, C.F.; Chang, H.T.
Eosinophil-derived neurotoxin is elevated in patients with amyotrophic lateral sclerosis. Mediat. Inflamm.
2013, 2013, 421389. [CrossRef] [PubMed]
82. Rentzos, M.; Nikolaou, C.; Rombos, A.; Boufidou, F.; Zoga, M.; Dimitrakopoulos, A.; Tsoutsou, A.;
Vassilopoulos, D. Rantes levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic
lateral sclerosis. Amyotroph. Lateral Scler. 2007, 8, 283–287. [CrossRef] [PubMed]
83. Schroder, T.; Fuchss, J.; Schneider, I.; Stoltenburg-Didinger, G.; Hanisch, F. Eosinophils in hereditary and
inflammatory myopathies. Acta Myol. 2013, 32, 148–153. [PubMed]
84. Sunohara, N.; Furukawa, S.; Nishio, T.; Mukoyama, M.; Satoyoshi, E. Neurotoxicity of human eosinophils
towards peripheral nerves. J. Neurol. Sci. 1989, 92, 1–7. [CrossRef]
85. Kingham, P.J.; McLean, W.G.; Walsh, M.T.; Fryer, A.D.; Gleich, G.J.; Costello, R.W. Effects of eosinophils on
nerve cell morphology and development: The role of reactive oxygen species and p38 MAP kinase. Am. J.
Physiol. Lung Cell. Mol. Physiol. 2003, 285, L915–L924. [CrossRef] [PubMed]
86. Walsh, M.T.; Curran, D.R.; Kingham, P.J.; Morgan, R.K.; Durcan, N.; Gleich, G.J.; McLean, W.G.; Costello, R.W.
Effect of eosinophil adhesion on intracellular signaling in cholinergic nerve cells. Am. J. Respir. Cell Mol. Biol.
2004, 30, 333–341. [CrossRef] [PubMed]
87. Yu, C.; Cantor, A.B.; Yang, H.; Browne, C.; Wells, R.A.; Fujiwara, Y.; Orkin, S.H. Targeted deletion of a
high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage
in vivo. J. Exp. Med. 2002, 195, 1387–1395. [CrossRef] [PubMed]
88. Burzyn, D.; Kuswanto, W.; Kolodin, D.; Shadrach, J.L.; Cerletti, M.; Jang, Y.; Sefik, E.; Tan, T.G.; Wagers, A.J.;
Benoist, C.; et al. A special population of regulatory T cells potentiates muscle repair. Cell 2013, 155,
1282–1295. [CrossRef] [PubMed]
89. Kuswanto, W.; Burzyn, D.; Panduro, M.; Wang, K.K.; Jang, Y.C.; Wagers, A.J.; Benoist, C.; Mathis, D.
Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent accumulation
of regulatory T cells. Immunity 2016, 44, 355–367. [CrossRef] [PubMed]
90. Lin, C.Y.; Pfluger, C.M.; Henderson, R.D.; McCombe, P.A. Reduced levels of interleukin 33 and increased
levels of soluble ST2 in subjects with amyotrophic lateral sclerosis. J. Neuroimmunol. 2012, 249, 93–95.
[CrossRef] [PubMed]
91. Gadani, S.P.; Walsh, J.T.; Smirnov, I.; Zheng, J.; Kipnis, J. The glia-derived alarmin IL-33 orchestrates the
immune response and promotes recovery following CNS injury. Neuron 2015, 85, 703–709. [CrossRef]
[PubMed]
92. Chapuis, J.; Hot, D.; Hansmannel, F.; Kerdraon, O.; Ferreira, S.; Hubans, C.; Maurage, C.A.; Huot, L.;
Bensemain, F.; Laumet, G.; et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for
alzheimer’s disease. Mol. Psychiatry 2009, 14, 1004–1016. [CrossRef] [PubMed]
93. Jiang, H.R.; Milovanovic, M.; Allan, D.; Niedbala, W.; Besnard, A.G.; Fukada, S.Y.; Alves-Filho, J.C.; Togbe, D.;
Goodyear, C.S.; Linington, C.; et al. IL-33 attenuates eae by suppressing IL-17 and IFN-γ production and
inducing alternatively activated macrophages. Eur. J. Immunol. 2012, 42, 1804–1814. [CrossRef] [PubMed]
94. Huang, P.L.; Hou, M.S.; Wang, S.W.; Chang, C.L.; Liou, Y.H.; Liao, N.S. Skeletal muscle interleukin 15
promotes CD8+ T-cell function and autoimmune myositis. Skelet. Muscle 2015, 5, 33. [CrossRef] [PubMed]
95. Lutz, C.T.; Quinn, L.S. Sarcopenia, obesity, and natural killer cell immune senescence in aging: Altered
cytokine levels as a common mechanism. Aging 2012, 4, 535–546. [CrossRef] [PubMed]
96. Rentzos, M.; Rombos, A.; Nikolaou, C.; Zoga, M.; Zouvelou, V.; Dimitrakopoulos, A.; Alexakis, T.;
Tsoutsou, A.; Samakovli, A.; Michalopoulou, M.; et al. Interleukin-15 and interleukin-12 are elevated
in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur. Neurol. 2010, 63, 285–290.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 631 16 of 16
97. Gustafson, M.P.; Staff, N.P.; Bornschlegl, S.; Butler, G.W.; Maas, M.L.; Kazamel, M.; Zubair, A.;
Gastineau, D.A.; Windebank, A.J.; Dietz, A.B. Comprehensive immune profiling reveals substantial immune
system alterations in a subset of patients with amyotrophic lateral sclerosis. PLoS ONE 2017, 12, e0182002.
[CrossRef] [PubMed]
98. Valdez, G.; Tapia, J.C.; Lichtman, J.W.; Fox, M.A.; Sanes, J.R. Shared resistance to aging and ALS in
neuromuscular junctions of specific muscles. PLoS ONE 2012, 7, e34640. [CrossRef] [PubMed]
99. Holtman, I.R.; Raj, D.D.; Miller, J.A.; Schaafsma, W.; Yin, Z.; Brouwer, N.; Wes, P.D.; Moller, T.; Orre, M.;
Kamphuis, W.; et al. Induction of a common microglia gene expression signature by aging and
neurodegenerative conditions: A co-expression meta-analysis. Acta Neuropathol. Commun. 2015, 3, 31.
[CrossRef] [PubMed]
100. Hammarberg, H.; Lidman, O.; Lundberg, C.; Eltayeb, S.Y.; Gielen, A.W.; Muhallab, S.; Svenningsson, A.;
Linda, H.; van Der Meide, P.H.; Cullheim, S.; et al. Neuroprotection by encephalomyelitis: Rescue of
mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells.
J. Neurosci. 2000, 20, 5283–5291. [PubMed]
101. Gross, C.C.; Schulte-Mecklenbeck, A.; Wiendl, H.; Marcenaro, E.; Kerlero de Rosbo, N.; Uccelli, A.; Laroni, A.
Regulatory functions of natural killer cells in multiple sclerosis. Front. Immunol. 2016, 7, 606. [CrossRef]
[PubMed]
102. Jadidi-Niaragh, F.; Shegarfi, H.; Naddafi, F.; Mirshafiey, A. The role of natural killer cells in Alzheimer’s
disease. Scand. J. Immunol. 2012, 76, 451–456. [CrossRef] [PubMed]
103. Lincecum, J.M.; Vieira, F.G.; Wang, M.Z.; Thompson, K.; De Zutter, G.S.; Kidd, J.; Moreno, A.; Sanchez, R.;
Carrion, I.J.; Levine, B.A.; et al. From transcriptome analysis to therapeutic anti-CD40l treatment in the SOD1
model of amyotrophic lateral sclerosis. Nat. Genet. 2010, 42, 392–399. [CrossRef] [PubMed]
104. Pfohl, S.R.; Halicek, M.T.; Mitchell, C.S. Characterization of the contribution of genetic background
and gender to disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis:
A meta-analysis. J. Neuromuscul. Dis. 2015, 2, 137–150. [CrossRef] [PubMed]
105. Murdock, B.J.; Bender, D.E.; Kashlan, S.R.; Figueroa-Romero, C.; Backus, C.; Callaghan, B.C.; Goutman, S.A.;
Feldman, E.L. Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis.
Neurol. Neuroimmunol. Neuroinflamm. 2016, 3, e242. [CrossRef] [PubMed]
106. Rusconi, M.; Gerardi, F.; Santus, W.; Lizio, A.; Sansone, V.A.; Lunetta, C.; Zanoni, I.; Granucci, F. Inflammatory
role of dendritic cells in amyotrophic lateral sclerosis revealed by an analysis of patients’ peripheral blood.
Sci. Rep. 2017, 7, 7853. [CrossRef] [PubMed]
107. Henkel, J.S.; Beers, D.R.; Wen, S.; Rivera, A.L.; Toennis, K.M.; Appel, J.E.; Zhao, W.; Moore, D.H.; Powell, S.Z.;
Appel, S.H. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival.
EMBO Mol. Med. 2013, 5, 64–79. [CrossRef] [PubMed]
108. Cudkowicz, M.E.; Shefner, J.M.; Schoenfeld, D.A.; Zhang, H.; Andreasson, K.I.; Rothstein, J.D.;
Drachman, D.B. Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. 2006, 60, 22–31. [CrossRef]
[PubMed]
109. Calvo, A.; Moglia, C.; Balma, M.; Chio, A. Involvement of immune response in the pathogenesis of
amyotrophic lateral sclerosis: A therapeutic opportunity? CNS Neurol. Disord. Drug Targets 2010, 9,
325–330. [CrossRef] [PubMed]
110. Smith, S.A.; Miller, R.G.; Murphy, J.R.; Ringel, S.P. Treatment of ALS with high dose pulse cyclophosphamide.
J. Neurol. Sci. 1994, 124, 84–87. [CrossRef]
111. Werdelin, L.; Boysen, G.; Jensen, T.S.; Mogensen, P. Immunosuppressive treatment of patients with
amyotrophic lateral sclerosis. Acta Neurol. Scand. 1990, 82, 132–134. [CrossRef] [PubMed]
112. Crisafulli, S.G.; Brajkovic, S.; Cipolat Mis, M.S.; Parente, V.; Corti, S. Therapeutic strategies under
development targeting inflammatory mechanisms in amyotrophic lateral sclerosis. Mol. Neurobiol. 2017.
[CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
